Method for producing TNF receptor releasing enzyme
Patent 6955894 Issued on October 18, 2005. Estimated Expiration Date: May 14, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE536/23.5, Encodes an animal polypeptide530/350PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES
The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
Other References
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234.
Gonzalez et al. (1985) “Variation among human 28S ribosomal genes.” Proceedings of the National Academy of Sciences of USA, vol. 82:7666-7670.
Katsura et al. (1996) “Identification of the proteolytic enzyme which cleaves human p75 TNG receptor in vitro.” Biochem. And Biophys. Research Communications, vol. 222(278):298-302.
Minet et al. (1990) “Cloning and sequencing of a human cDNA coding for a multifunctional polypeptide of the purine pathway by complementation of the ade2.101 mutant in Saccharomyces cerevisiae.” Curr. Genet., vol. 18:287-291.
Oshima et al. (1988) “The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in cos cells.” The Journal of Biological Chemistry, vol. 5:2553-2562.
Porteu et al. (1991) “Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor.” The Journal of Biological Chemistry, vol. 266:18846-18853.
(2000) “ENBREL(R) (etanercept) U.S. and European Long-Term Clinical Trial Data Presented at the Annual Meeting of the European League Against Rheumatism.” Company News On-Call http://www.prnewswire.com/cgi-bin/stories.pl?Acct=105&Story=/www/story/06.23.2000/0001250565 (Jun. 23, 2000).
Abraham et al., “p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock”,. (1997) JAMA 277:1531-1538.
Aderka et al., “Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients” (1991) Cancer Res. 51:5602-5607.
Aderka et al., “Variation in serum levels of the soluble INF receptors among healthy individuals.” (1992) Lymphokine Cytokine Res. 11:157-159.
Alderson et al., “Regulation of human monocyte cell-surface and soluble CD23 (FCεRII) by granulocyte-macrophage colony-stimulating factor and IL-33” (1992) J. Immunol., 149:1252-1257.
Arbor et al., “Effects of tumour necrosis factor-α (cachectin) on glucose metabolism in the rat” (1992) Mol. Cell. Biochem., 112:53-59.
Argiles et al. (1988) “The metabolic environment of cancer.” Mol. Cell. Biochem., vol. 81:3-17.
Argiles et al., “Journey from cachexia to obesity by TNF” (1997) FASEB.J. , 11:743-751.
Armitage (1994) Tumor necrosis factor receptor superfamily members and their ligands. (1994) Curr. Opin. Immunul. 6:407-413.
Arner (1996) “Obesity and Insulin Resistance in Swedish Subjects” Diabetes Metabl., vol. 13:S85-S86.
Ashkenazi et al. (1991) “Protection against endotoxic chock by a tumor necrosis factor receptor immunoadhesin.” Proc. Natl. Acad. Sci. USA, vol. 88:10535-10539.
Banner et al. (1993) “Crystal structure of the soluble human 55 kd receptor-human TNFβ complex: Implications for TNF receptor activation.” Cell, vol. 73:431-445.
Baran et al. (1988) “Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.” J. Immunol, vol. 141:539-546.
Bauditz et al. (1997) “Treatment with tumour necrosis factor inhibitor oxpetifylline does not improve corticosteroid dependent chronic active Crohn's disease.” Gut, vol. 40:470-474.
Baum et al (1994) “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.” EMBO J., vol. 13:3992-4001.
Beretz et al. (1990) “Modulation by cytokines of leukocyte-endothelial cell interactions, implications for thrombosis.” Biorheology, vol. 27:455-460.
Bermudez et al., “Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor” (1990) Lymphokine Res. 9:137-145.
Beutler et al., “Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin” (1985) Science 229:869-1371.
Bianchi et al., “Increased Brown adipose tissue activity in children with malignant disease” (1989) Horm. Metab. Res., 21:640-41.
Birkedal-Hansen et al., “Matrix metalloproteinases: A review.” (1993) Crit. Rev. Oral Biol. Med., vol. 4:197-250.
Bogdan et al. (1991) “Macrophage deactivation by interleukin 10” J. Exp. Med., vol. 174:1549-1555.
Brockhaus et al. (1990) “Identification of 2 types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.” Proc. Natl. Acad. Sci. USA, vol. 87:3127-3131.
Buck et al. (1996) “Tumor necrosis factor-α inhibits collagen α1(1)gene expression and wound healing in a murine model of cachexia.” Am. J. Pathol., vol. 149:195-204.
Calvano et al. (1996) “Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis.” Arch. Surg., vol. 131:434-437.
Carcoran et al. (1994) “Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor.” Eur. J. Biochem., vol. 223:831-840.
Chitambar (1991) “Shedding of transferring receptor from rat reticulocytes during maturation in vitro: Soluble transferring receptor is derived from receptor shed in vesicles.” Blood, vol. 78:2444-2450.
Colotta et al. (1993) “Interleukin-1 type II receptor: A decoy target of IL-1 that is regulated by IL-4.” Science, vol. 261:472-475.
Cornelius et al “Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor” (1988) Biochem. J. 249:765-769.
Cosman, “A family of ligands for the TNF receptor superfamily” (1994) Stem cells (Dayt.) 12:440-455.
Costelli et al., “Tumor necrosis factor-α mediates change in tissue protein turnover in a rat cancer cachexia model” (1993) J. Clin. Invest. 92:2783-2789.
Crowe et al., “A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T-lymphocytes” (1995) J. Exp. Med., 181:1205-1210.
de Waal Malefyt et al., “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory rule of Il-10 produced by monocytes” (1991) J. Exp. Med., 174:1209-1220.
Dean et al., “Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage” (1989) J. Clin. Invest. 84:678-85.
Dembic et al. “Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences” (1990) Cytokine, 2:231-237.
Derkx et al., “High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock” (1995) J. Infect. Dis. 171:229-232.
Dessi et al. “Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130)” (1995) Br. J. Cancer 72:11.38-1143.
Dett et al., “Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1β, IL-4, and IL-6 in vitro” (1991) J. Immunol. 146:1522-1526.
Diez-Ruiz et al., “Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis” (1995) Eur. J. Haematol. 54:1-8.
Driscoll, K., “Macrophage; inflammatory proteins” (1994) Exp. Lung Res. 20:474-490.
Dubravec et al., “Circulating human peripheral blood granulocytes synthesis and secrete tumor necrosis factor α.” (1990) Proc. Natl. Acad. Sci. USA 87:6768-6761.
Durez et al., “In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: Differential modulation by cyclosporin A” (1993) J. Exp. Med. 177:551-555.
Echtenacher et al. (1996) “Critical productive role of mast cells in a model of acute septic peritonitis.” Nature, vol. 381:75-77.
Engelmann et al. (1989) “A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.” J. Biol. Chem., vol. 264:11974-11980.
Engelmann et al. (1990) “Two tumor necrosis factor-binding proteins purified from human urine.” J. Biol. Chem., vol. 265:1531-1536.
Ertel et al. (1994) “Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis.” Arch. Surg., vol. 129:1330-1337.
Evans et al. (1988) “Tumour necrosis factor I (cachetin) mimics some of the effects of tumour growth on the disposal of a [14C] lipid load in virgin, lactating and litter-removed rats.” Biochem. J., vol. 256:1055-1058.
Fargeas et al. (1993) “Central action of interleukin 1 on intestinal motility in rats: Mediation by two mechanisms.” Gastroenterology, vol. 104:377-383.
Feingold et al. (1992) “Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis.” Endocrinology, vol. 130:10-16.
Fenner (1995) “TNF-inhibitoren: Eine neue therapeutische perspective bei chronischentzundlichen Erkrankungen in der Rheumatologie?” Z. Rheumatol., vol. 54:158-164.
Ferrante (1992) “Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors.” Immunol. Ser., vol. 57:417-436.
Fiers (1991) “Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level.” FEBS Letters, vol. 285:199-212.
Fiorentino et al. (1991) “IL-10 inhibits cytokine production by activated macrophages.” J. Immunol., vol. 147:3815-3822.
Fisher et al. (1996) “Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein.” N. Engl. J. Med., vol. 334:1697-1702.
Fried et al. (1989) “Cachetin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity.” J. Lipid Res., vol. 30:1917-1923.
Fukunaga et al. (1990) “Three different mRNAs encoding human granulocyte colony-stimulating factor receptor.” Proc. Natl. Acad. Sci. USA, vol. 87:8702-8706.
Garcia-Martinez et al. (1993) “Tumour necrosis factor-I increased the ubiquitinization of rat skeletal muscle proteins.” FEBS Letters., vol. 323:211-214.
Gatanaga et al. (1990) “Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients.” Lymphokine Res., vol. 9:225-229.
Gatanaga et al. (1990) “Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.” Proc. Natl. Acad. Sci. USA, vol. 87:8781-8784.
Gatanaga et al. (1991) “The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA— and LPS-stimulated human monocytic THP-1 cells in vitro.” Cell Immunol., vol. 138:1-10.
Gatanaga et al. (1993) “Release of soluble TNF/LT receptors from a human ovarian tumor cell line (PA-1) by stimulation with cytokines in vitro.” Lymphokine and Cytokine Res., vol. 12:249-253.
Gearing et al. (1994) “Processing of tumour necrosis factor-I precursor by metalloproteinases.” Nature, vol. 370:555-557.
Gearing et al. (1995) “Matrix metalloproteinases and processing of pro-TNF-I.” J. Leukoc. Biol., vol. 57:774-777.
Gehr et al. (1992) “Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell actiation.” J. Immunol., vol. 149:911-917.
Gerard et al. (1993) “Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.” J. Exp. Med., vol. 177:547-550.
Golstein et al. (1991) “Cell death mechanisms and the immune system.” Immunol. Rev., vol. 121:29-65.
Goodman (1991) “Tumor necrosis factor induces skeletal muscle protein breakdown in rats.” Am. J. Physiol., vol. 260:E727-730.
Goodwin et al. (1990) “Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily.” Cell, vol. 60:941-951.
Gorton et al., “Mast cells as a source of preformed and immunologically inducible TNF-I /cachetin” (1990) Nature 346:274-276.
Grau et al., “Tumor necrosis factor (cachetin) as an essential, mediator in murine cerebral malaria” (1987) Science 237:1210-1212.
Grell et al., “Segregation of APO-1 /Fas antigen- and tumor necrosis factor receptor-mediated apoptosis” (1994) Euro. J. Immunol. 24:2563-2566.
Grosen et al., “Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy” (1993) Gynecol. Oncol. 50:68-77.
Grunfeld et al., “Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters” (1996) J. Clin. Invest. 97:2152-2157.
Gullberg ct al., “Involvement of an Asn/Gal cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain” Eur. J. Cell. Biol. (1992) 58:307-312.
Hahne et al., “A novel soluble form of mouse VCAM-1 is generated from a glycolipid-anchored splicing variant” (1994) Eur. J. Immunol. 24:421-428.
Halwachs et al., “Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease” (1994) Clin. Investig. 72:473-476.
Hauner et at, Effects of tumour necrosis factor alpha (TNFI ) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture (1995) Diabetologia 38:764-771.
Heller et al., “Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor” (1990) Proc. Natl. Acad. Sci. USA 87:6151-6155.
Henney et al., “Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization” (1991) Proc. Natl. Acad. Sci. USA 88:8154-8158.
Hillier et al. (1996) “Generation and analysis of 280,000 human expressed sequence tags.” Genome Research, vol. 6(9):807-828.
Himmler et al., “Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein” (1990) DNA Cell Biol. 9:705-715.
Hintzen et al., “Characterization of the human CD27 ligand, a novel member of the TNF gene family” (1994) J. Immunol. 152:1762-1773.
Hjemdahl et al., “9-adrenoceptors in human alveolar macrophages isolated by elutriation” (1990) Br. J. Clin. Pharmacol. 30:673-682.
Hofmann et al., “Altered gene expression for tumor necrosis factor-1 and it receptors during drug and dietary modulation of insulin resistance” (1994) Endocrinology 134:264-270.
Holtmann et al., (1987) J. Immunol. 139:151-153.
Hotamisligil et al., “Increased adipose tissue expression of tumor necrosis in human obesity and insulin resistance” (1995) J. Clin. Invest. 95:2409-2415.
Howard et al., “Interleukin 10 protects mice from lethal endotoxemia” (1993) J. Exp. Med. 177:1205-1208.
Hu et al., “The effect of norepinephrine on endotoxin-mediated macrophage activation” (1991) J. Neuroimmunol 31:35-42.
Huizinga et al., “The PI-linked receptor FcRIII is released on stimulation of neutrophils” (1988) Nature 333:667-669.
Jin et al., “Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: Comparison with anti-TNF monoclonal antibody” (1994) J. Infect. Dis. 170:132 3-1326.
Joyce et al., “Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytcs” (1994) Eur. J. Immunol. 24:2699-2705.
Kalinkovich et.al. “Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection” (1995) J. Interferon Cyto. Res, 15;749-757.
Katsura et al. (1996) “Identification and characterization of soluble TNF receptor releasing enzyme (TRRE) from PMA-stimulated human monocytic THP-1 cells.” Proc. Amer. Cancer Res. Meeting, vol. 37:492.
Kawakami et al. (1987) “Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-LT cells.” J. Biochem., vol. 101:331-338.
Khire et al. (1990) “EGF stimulates the processing and export of a secreted from of EGF receptor.” Febs. Lett., vol. 272:69-72.
Khokha et al. (1989) “Antisense RNA-induced reduction in murine TIMP leves confers oncogenicity on Swiss 3T3 cells.” Science, vol. 243:947-950.
Klinkert et al. (1997) “TNR-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview.” J. Neuroimmun., vol. 72:163-168.
Kohno et al. (1990) “A second tumor necrosis factor receptor gene product can shed a naturally occuring tumor necrosis factor inhibitor.” Proc. Natl. Acad. Sci. USA vol. 87:8331-8335.
Kriegler et al. (1988) “A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF.” Cell, vol. 53:45-53.
Lambert et al. (1994) “Natural serum TNF antagonists in end-stage renal failure and following renal transplantation.” Nephrol. Dia. Transplant., vol. 9:1791-1796.
Landmann et al. (1992) “Interferon-γ and interleukin-4 down-regulate soluble CD14 release in human monocytes and macrophages.” J. Leukoc. Biol., vol. 52:323-330.
Latza et al. (1995) “CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.” Am. J. Pathol., vol. 146:463-471.
Lawson et al. (1982) “Metabolic approaches to cancer cachexis.” Annu. Rev. Nutr., vol. 2:277-301.
Leeuwenberg et al. (1994) “Slow release of soluble TNF receptors by monocytes in vitro.” J. Immunol., vol. 152:4036-4043.
Leffers (1993) “The sequence of 28S ribosomal RNA varies within and between human cell lines.” Nucleic Acid Research, vol. 21(6):1449-1455.
Lesslauer et al. (1991) “Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality.” Eur. J. Immunol., vol. 21:2883-2886.
Lesslauer, et al., “Recombinant soluble tumor necrosis factor recepotr proteins protect mice form lipopolysaccharide-induced lethality,” Eur. J. Immunol. (1991) vol. 21:2883-2886.
Llovera et al. (1993) “Effects of tumor necrosis factor-α on muscle-protein turnover in female Wistar rats.” J. Natl. Cancer Inst., vol. 85:1334-1339.
Loenen et al. (1992) “The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that odes not involve receptor endocytosis.” Eur. J. Immunol., vol. 22:447-455.
Loetscher et al. (1990) “Molecular Cloning can expression of the human 55kd tumor necrosis factor receptor.” Cell, vol. 61:351-359.
Loetscher et al. (1990) “Purification and partial amino aicd sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.” J. Biol. Chem., vol. 265:20131-20138.
Lopez-Casillas et al. (1991) “Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system.” Cell, vol. 67:785-795.
Lovejoy et al. (1994) “Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor.” Science, vol. 263:375-377.
Lowry et al. (1992) “Metal ion stabilization of conformation of a recombinant 19-kDa catalytic fragment of human fibroblast collagenase.” Proteins, vol. 12:42-48.
Madej et al. (1995) “Threading analysis suggests that the obese gene product may be a helical cytokine.” FEBS Lett., vol. 373:13-18.
Marchant et al. (1994) “Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia.” Eur. J. Immunol., vol .24:1167-1171.
Marchant et al. (1994) “Interleukin-10 production during septicaemia.” Lancet, vol. 343:707-708.
Matrisian (1990) “Metalloproteinases and their inhibitors in matrix remodeling,” Trends Genet., vol. 6:121-125.
Meakin et al. (1992) “The nerve growth factor family of receptors.” Trends Neurosci., vol. 15:323-331.
Michie et al. (1988) “Detection of circulating tumor necrosis factor after endotoxin administration.” New Engl. J. Med., vol. 318:1481-1486.
Mignatti et al. (1986) “Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade.” Cell, vol. 47:487-498.
Miles et al. (1992) “Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.” Br. J. Cancer, vol. 66:1195-1199.
Mohler et al. (1993) “Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.” J. Immunol., vol. 151:1548-1561.
Mohler et al. (1994) “Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.” Nature, vol. 370:218-220.
Mohler, et al., “Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF Antagonists,” J. of Immunol. (Aug. 1, 1993) vol. 151(3):1548-1561.
Moller et al. (1994) “Expression of APO-1(CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium.” Int. J. Cancer, vol. 57:371-377.
Moore (1993) “Interleukin-10” Annu. Rev. Immunol., vol. 11:165-190.
Moreland et al. (1997) “Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75).Fc fusion protein.” N. Eng. J. Med., vol. 337:141-147.
Morgan et al. (1987) “Insulin-like growth factor II receptor as a multifunctional binding protein.” Nature, vol. 329(6137):301-307.
Mosley et al. (1989) “The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms.” Cell, vol. 59:335-348.
Mullberg et al. (1995) “A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.” J. Immunol., vol. 155:5198-5205.
Neurath et al. (1997) “Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.” Eur. J. Immuno., vol. 27:1743-1750.
Nicholls (1983) “The thermogenic mechanism of brown adipose tissue.” Biosci. Rep., vol. 3:431-441.
Nophar et al. (1990) “Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.” EMBO J., vol. 9:3269-3278.
Novick et al. (1989) “Soluble cytokine receptors are present in normal human urine.” J. Exp. Med., vol. 170:1409-1414.
Ogiwara et al. (1994) “Diminished visceral adipose tissue in cancer cachexia.” J. Surg. Oncol., vol. 57:129-133.
Old (1987) “Another chapter in the long history of endothoxin.” Nature, vol. 330:602-603.
Oliff et al. (1987) “Tumors secreting human TNF/cachecin induce cachexia in mice,” Cell, vol. 50:555-563.
Olsson et al. (1992) “Isolation and characterization of a tumor necrosis factor binding protein from urine.” Eur. J. Haematol., vol. 42:270-275.
Olsson et al. (1992) “The receptors for regulatory molecules of hematopoiesis.” Eur. J. Haematol., vol. 48:1-9.
Olsson et al. (1993) “Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and maligancy.” Eur. Cytokine Netw., vol. 4:169-180.
Oudart et al. (1995) “Stimulation of brown adipose tissue activity in tumor-bearing rats.” Can. J. Physiol. Pharmacol., vol. 73:1625-1631.
Pandiella et al. (1991) “Cleavage of the membrane precursor for transforming growth factor α is a regulated process.” Proc. Natl. Acad. Sci. USA, vol. 88:1726-1730.
Peetre et al. (1988) “A tumor necrosis factor binding protein is present in human biological fluids.” Eur. J. Haematol., vol. 41:414-419.
Phillips et al. (1996) “Leptin receptor missense mutation in the fatty Zucker rat” Nature Genet., vol. 13:18-19.
Plata-Salaman et al. (1994) “Chemokines/intercrines and central regulation of feeding.” Am. J. Physiol., vol. 266:R1711-R1715.
Porat et al. (1995) “Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis.” Crit. Care Med., vol. 23:1080-1089.
Porteu (1994) “Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils.” J. Biol. Chem., vol. 269:2834-2840.
Porteu et al. (1990) “Shedding of tumor necrosis factor receptors by activated human neutrophils.” J. Exp. Med., vol. 172:599-607.
Price et al. (1986) “Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor—the primary regulatory role of the hormone in 3T3-LT adipocytes.” Arch. Biochem. Biophys., vol. 251:783-746.
Raines et al. (1991) “Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor.” Proc. Natl. Acad. Sci. USA, vol. 88:8203-8207.
Renauld et al. (1992) “Expression cloning of the murine and human interleukin 9 receptor cDNAs” Proc. Natl. Acadi. Sci. USA, vol. 89:5690-5694.
Rose-John et al. (1994) “Soluble receptor for cytokines and growth factors: generation and biological function.” Biochem. J., vol. 300:281-290.
Rothwell (1993) “Cytokines and thermogenesis.” Int. J. Obesity, vol. 17:S98-101.
Saghizadeh et al. (1996) “The expression of TNF-α by human muscle: Relationship to insulin resistance.” J. Clin. Invest., vol. 97:1111-1116.
Satal et al. (1996) “Hemostatic parameters in sepsis patients treated with anti-TNFα-monoclonal antibodes.” Shock, vol. 6:233-237.
Schall et al. (1990) “Molecular cloning and expression of recepetor for human tumor necrosis factor.” Cell, vol. 61:361-370.
Schwartz et al. (1995) “Hypothalamic response to starvation : implications for the study of wasting disorders.” Am. J. Physiol., vol. 269:R949-957.
Scuderi et al. (1986) “Raised serum levels of tumour necrosis factor in parasitic infections.” Lancet, Dec. 13:1364-1365.
Seckinger et al. (1988) “A human inhibitor of tumor necrosis factor α.” J. Exp. Med., vol. 167:1511-1516.
Seckinger et al. (1989) “Purification and biologic characterization of a specific tumor necrosis factor α inhibitor.” J. Biol. Chem., vol. 264:11966-11973.
Seitz et al. (1997) “In vitro modulations of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs.” J. Rheumatology, vol. 24:1471-1476.
Semb et al. (1987) “Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo.” J. Biol. Chem., vol. 262:3890-3894.
Senior et al. (1989) “Elastin degradation by human alveolar macrophages.” Am. Rev. Respir. Dis., vol. 139:1251-1256.
Seth et al. (1991) “Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders.” Lancet, vol. 338:83-84.
Severn, et al. “Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists” (1992) J. Immunol, 148:3441-3445.
Shalaby et al., “Binding and regulation of cellular functions by monoclonal; antibodies against human tumor necrosis factor receptors” (1990) J. Exp. Med, 172:1517-1520.
Shohami et al., “Cytokine production in the brain following; closed head injury: dexanabinol (HU—211) is a novel TNF-α inhibitor and an effective neuroprotectant” (1997) J. Neuroimmun. 72:169-177.
Simon et al.; “Divergent T-cell cytokine patterns in inflammatory arthritis” (1994) Proc. Natl. Acad. Sci. USA 91:862.
Smith et al., “A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins” (1990) Science 248:1019-1023.
Smith et al., “CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with Homology to TNF” (1993) Cell 73:1349-1360.
Speiser et al., “TNF receptor p55 controls early acute graft-versus-host disease” (1997) J. Immun. 158:5185-5190.
Spengler et al., “Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro” (1994) J. Immunol. 152:3024-3031.
Spiegelmam et al., “Through thick and thin: Wasting, obesity, and TNFα” (1993) Cell ,73:625-627.
Stack et al., “Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease” (1997) Lancet 349:521-524.
Stein et al., “Proteolytic processing of a plasma membrane-bonud precursor to human macrophage colony-stimulating factor (CSH-1) is accelerated by phorbol ester” (1991) Oncogene 6:601-605.
Takaki et al, “Molecular cloning and expression of the murine interleukin-5 receptor” (1990) EMBO J. 9:4367-4374.
Talmadge et al., “Molecular pharmacology of the beta-adrenergic receptor oil THP-1 cells” (1993) Int. J. Immunopharmacol. 15:219-228.
Tartaglia et al., “The two different receptors for tumor necrosis factor mediate distinct cellular responses” (1991) Proc. Natl. Acad. Sci. USA 88:9292-9296.
Tartaglia et al., “Two TNF receptors” (1992) Immunol. Today 13:151-153.
Tiesman et al., “Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma”, (1993) J. Biol. Chem., 268:9621-9628.
Tracey et al. “Cachectin/tumor necrosis factor induces lethal shock acid stress hormone responses in the dog” (1987) Surg. Gynecol. Obstet. 164:415-422.
Tracey et al., “Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia” (1987) Nature 330:662-664.
Trehu, et al., “Phase I trail of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeria,” (Aug. 1996) vol. 2:1341-1351.
van der Poll et al., “Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense?” (1995) Shock—3:1-12.
van der Poll ct al., “Endogenous IL-10 protects mice from death during septic peritonitis” (1995) J. Immunol. 155:5397-5401.
van Deuren; “Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections” (1994) Eur. J. Clin. Microbiol. Infect. Dis. 13 (Suppl. 1):S12-S16.
van Deventer et al., “Monoclonal antibody therapy of inflammatory bowel disease” (1997) Pharm. World.Sci. 19:55-59.
Van Hogezand et al., “New therapies for inflammatory bowel disease: an update on chimeric anti-TNFα antibodies and IL-10 therapy” (1997) Scand. J. Gastro. 223:105-107.
Van. Zee et al., “Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive: tumor necrosis factor a in vitro and in vivo”(1992) Proc. Natl. Acad Sci. USA 89:4845-4849.
Waage et aL, “Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients” (1986) Scand. J. Immunol. 24:739-743.
Woesser, Jr. “Matrix metalloproteinases and their inhibitors in connective tissue remodeling” (1991) FASEB J. 5:2145-2154.
Yamamoto,et al., “FR167653, a dual inhibitor of interleukin-1 and tumor neurosis factor-α, ameliorates endotoxin-induced shock” (1997) Eur. J. Pharmacol 327:169-175.
Yui et al., “Cytotoxicity of tumour necrosis factor-alpha and gamma-interferon against primary human placental trophoblasts” (1994) Placenta 15:819-835.
Zamir et al., “Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis” (1992) Arch. Surg. 127:170-174.
Zhang et al., “Positional cloning of the mouse obese gene and its human, homologue” (1994) Nature 372:425-432.
Zupan et al., “Identification, purification, and characterization of truncated forms of the human nerve growth, factor receptor,” (1989) J. Biol. Chem. 264:11714-11720.
May 14, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
